First-in-class biologic to enter rheumatoid arthritis fray

Article Abstract:

A novel biologic for the treatment of rheumatoid arthritis (RA) is set to enter the US market after a US Food and Drug Administration (FDA) committee recommended approval for Bristol-Myers Squibb's fusion protein Orencia (abatacept) in September 2005. Other new treatments are likely to follow, challenging the dominance of tumor necrosis factor (TNF) blockers such as Centocor's Remicade.

United States, Product development, Government regulation, Pharmaceutical preparations, Pharmaceutical industry, Drug therapy, Rheumatoid arthritis, Licensing, certification and accreditation, Bristol-Myers Squibb Co., BMY, United States. Food and Drug Administration, Orencia (Medication)

---

Hepatitis C: staying the course

Article Abstract:

An estimate of 170 million people worldwide are infected with hepatitis C virus (HCV) and the number facing death or serious liver diseases is increasing emphasizing the need for an effective treatment.

Science & research, Labor Distribution by Employer, Care and treatment, Research, Statistics, Hepatitis C

---

Similar abstracts:

• Abstracts: The patentability of human embryonic stem cells in Europe. FDA likely to further restrict erythropoietin use for cancer patients
• Abstracts: As products enter clinic... scientists shown the door. Ian Frazer. Syrrx acquisition signals maturation of structure-based discovery
• Abstracts: Biotech consulting, investing by NIH scientists curbed. The business of developing antibacterials. Lester Crawford

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.